LI Wei,HE Liqun,ZHANG Fan.Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome[J].Medical Journal of Wuhan University,2025,46(10):1301-1306.
LI Wei,HE Liqun,ZHANG Fan.Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome[J].Medical Journal of Wuhan University,2025,46(10):1301-1306.DOI: 10.14188/j.1671-8852.2024.0663.
Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome
To explore the expression and significance of long non‑coding RNA (lncRNA) TPRG1‑AS1 in the pathogenesis and development of acute coronary syndrome (ACS)
in order to explore a novel biomarker for the diagnosis and prognosis of acute coronary syndrome.
Methods
2
A total of 109 patients with ACS and 66 patients receiving coronary angiography but excluding ACS were included in this study. The significance of TPRG1‑AS1 in screening ACS was evaluated by PCR analysis of serum TPRG1‑AS1 of the study subjects and ROC analysis. Pearson correlation test was used to evaluate the relationship between TPRG1⁃AS1 and disease severity of ACS. Logistic regression analysis was used to evaluate the potential relationship of TPRG1‑AS1 to predict the occurrence of major adverse cardiovascular events (MACE).
Results
2
The expression of TPRG1⁃AS1 in serum of patients with ACS was significantly up‑regulated
which is a risk factor for ACS. TPRG1‑AS1 is positively correlated with Gensini score
Cys⁃C
cTnI and NT‑proBNP levels of patients with ACS. In addition
elevated serum TPRG1‑AS1 is associated with a higher incidence of MACE during hospitalization and has been identified as a risk factor for MACE in patients with ACS.
Conclusion
2
The increase of serum TPRG1‑AS1 can be used as a biomarker for the diagnosis of ACS and has certain predictive value for the severity of the disease. Upregulated TPRG1‑AS1 in ACS served as a diagnostic biomarker and predicted the severe development of patients.
关键词
Keywords
references
AHMADI A , ARGULIAN E , LEIPSIC J , et al . From subclinical atherosclerosis to plaque progression and acute coronary events JACC state‑of‑the‑art review [J ] . J Am Coll Cardiol , 2019 , 74 ( 12 ): 1608 ‑ 1617 .
SMITH J N , NEGRELLI J M , MANEK M B , et al . Diagnosis and management of acute coronary syndrome: An evidence‑based update [J ] . J Am Board Fam Med , 2015 , 28 ( 2 ): 283 ‑ 293 .
BOYD B , ZAMORA C A , CASTILLO M . Managing adverse reactions to contrast agents [J ] . Magn Reson Imaging Clin N Am , 2017 , 25 ( 4 ): 737 ‑ 742 .
MARRACCINI P , BIANCHI M , FOMMEI E , et al . Contrast medium nephrotoxicity after renal artery and coronary angioplasty [J ] . Acta Radiol , 2010 , 51 ( 4 ): 462 ‑ 466 .
WANG L , JIN Y . Noncoding RNAs as biomarkers for acute coronary syndrome [J ] . Biomed Res Int , 2020 , 2020 : 3298696 .
LI L , WANG L Y , LI H F , et al . Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease [J ] . Atherosclerosis , 2018 , 275 : 359 ‑ 367 .
REN X , ZHU H , DENG K , et al . Long noncoding RNA TPRG1‑AS1 suppresses migration of vascular smooth muscle cells and attenuates atherogenesis via interacting with MYH9 protein [J ] . Arterioscler Thromb Vasc Biol , 2022 , 42 ( 11 ): 1378 ‑ 1397 .
CHOI J H , KWON S M , MOON S U , et al . TPRG1‑AS1 induces RBM24 expression and inhibits liver cancer progression by sponging miR‑4691‑5p and miR‑3659 [J ] . Liver Int , 2021 , 41 ( 11 ): 2788 ‑ 2800 .
HE J N , DONG C M , ZHANG H , et al . The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1‑AS1/DNMT3A/CRTAC1 axis [J ] . Cell Signal , 2023 , 102 : 110527 .
LI Z H , QIU X G , HE Q , et al . CCND1‑associated CeRNA network reveal the critical pathway of TPRG1‑AS1‑hsa‑miR‑363‑3p‑MYO1B as a prognostic marker for head and neck squamous cell carcinoma [J ] . Sci Rep , 2023 , 13 : 11831 .
KIMURA K , KIMURA T , ISHIHARA M , et al . JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome [J ] . Circ J , 2019 , 83 ( 5 ): 1085 ‑ 1196 .
CHHABRA S T , KAUR T , MASSON S , et al . Early onset ACS: An age based clinico‑epidemiologic and angiographic comparison [J ] . Atherosclerosis , 2018 , 279 : 45 ‑ 51 .
KRINGELAND E , TELL G S , MIDTBØ H , et al . Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland Health Study [J ] . Eur J Prev Cardiol , 2022 , 29 ( 1 ): 147 ‑ 154 .
MANFRINI O , CENKO E , BUGIARDINI R . Gender differences in residual risk factors for major adverse cardiovascular events following ACS and how to bridge the gap [J ] . Curr Atheroscler Rep , 2020 , 22 ( 11 ): 65 .
YAMAMOTO K , NATSUAKI M , MORIMOTO T , et al . Coronary artery disease without standard cardiovascular risk factors [J ] . Am J Cardiol , 2022 , 164 : 34 ‑ 43 .
CHEN J , ZHANG Y , LIU J , et al . Role of lipoprotein(a) in predicting the severity of new on‑set coronary artery disease in type 2 diabetics: A Gensini score evaluation [J ] . Diab Vasc Dis Res , 2015 , 12 ( 4 ): 258 ‑ 264 .
RAMPIDIS G P , BENETOS G , BENZ D C , et al . A guide for gensini score calculation [J ] . Atherosclerosis , 2019 , 287 : 181 ‑ 183 .
TANAKA T , MIKI K , AKAHORI H , et al . Comparison of coronary atherosclerotic disease burden between ST‑elevation myocardial infarction and non‑ST‑elevation myocardial infarction: Non‑culprit Gensini score and non‑culprit SYNTAX score [J ] . Clin Cardiol , 2021 , 44 ( 2 ): 238 ‑ 243 .
DOGANER Y C , AYDOGAN U , AYDOGDU A , et al . Relationship of cystatin C with coronary artery disease and its severity [J ] . Coron Artery Dis , 2013 , 24 ( 2 ): 119 ‑ 126 .
VAN DER LAAN S W , FALL T , SOUMARÉ A , et al . Cystatin C and cardiovascular disease: A mendelian randomization study [J ] . J Am Coll Cardiol , 2016 , 68 ( 9 ): 934 ‑ 945 .
WALLENTIN L , ERIKSSON N , OLSZOWKA M , et al . Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study [J ] . PLoS Med , 2021 , 18 ( 1 ): e1003513 .
WANG G N , SUN K , HU D L , et al . Serum cystatin C levels are associated with coronary artery disease and its severity [J ] . Clin Biochem , 2014 , 47 ( 16/17 ): 176 ‑ 181 .
ALMEIDA R , MARIANO L , GAVINA C , et al . The value of NT‑proBNP in early risk stratification of acute coronary syndromes [J ] . Rev Port Cardiol , 2006 , 25 ( 1 ): 71 ‑ 75 .
FAN J , MA J , XIA N , et al . Clinical value of combined detection of CK‑MB, MYO, cTnI and plasma NT‑proBNP in diagnosis of acute myocardial infarction [J ] . Clin Lab , 2017 , 63 ( 3 ): 427 ‑ 433 .
HAMAYA R , YONETSU T , KANAJI Y , et al . Interrelationship in the prognostic efficacy of regional coronary flow reserve, fractional flow reserve, high‑sensitivity cardiac troponin‑I and NT‑proBNP in patients with stable coronary artery disease [J ] . Heart Vessels , 2019 , 34 ( 3 ): 410 ‑ 418 .
NOPP S , VAN DER BENT M L , KRAEMMER D , et al . Circulatory miR‑411‑5p as a novel prognostic biomarker for major adverse cardiovascular events in patients with atrial fibrillation [J ] . Int J Mol Sci , 2023 , 24 ( 4 ): 3861 .
TANG Q J , LEI H P , WU H , et al . Plasma miR‑142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy [J ] . Acta Pharmacol Sin , 2019 , 40 ( 2 ): 208 ‑ 215 .